Introduction
One of the main aims of direct gene transfer in vascular biology is to evaluate the function of an individual gene by local overexpression in a complex model or system. A number of vector systems including replication-deficient adenoviruses have been developed to facilitate gene delivery into cells. To investigate the function of the transgene it is crucial that the vector itself does not alter the biological process being studied. It has recently been reported that the high adenoviral loads needed to achieve transgene expression have been associated with local inflammation after delivery into rabbit arteries 1 and the respiratory epithelium of both primates 2 and humans. 3 However, the precise mechanism underlying this inflammatory response remains obscure. The transcription factor NFB was initially described by its ability to augment the expression of the light chain gene in B lymphocytes. 4 In addition to its role in the immune response, NFB is known to induce the expression of a number of inflammatory response genes including the cell adhesion molecules intercellular adhesion molecule-1 (ICAM-1) 5 and vascular cell adhesion molecule-1 (VCAM-1), 6 as well as a number of cytokines including tumour necrosis factor-␣ (TNF␣), interleukin-1␤, interleukin-6 and interleukin-8. 7 Activation of NFB involves the dissociation of the p65/p50 active subunit from the inhibitory factor (I-B) in a process which does not require new protein synthesis by the cell. Rapid non-lysosomal, proteolytic degradation of I-B is an essential event in the activation of NFB which can be blocked by serine protease inhibitors such as N␣-p-tosyl-l-lysine chloromethyl ketone (TLCK) 8 ( Figure 1 ). Although known to be an important mediator of inflammation, little is known about the role of NFB activation in the inflammatory response following adenovirus-mediated gene delivery.
We have previously demonstrated that the promoter performance of the human cytomegalovirus immediateearly promotor (CMV-IEP) has a critical bearing on transduction efficiency after adenoviral vector delivery into human VSMCs. 9 Stimulation of NFB and CREB response elements in the CMV-IEP were required to unmask ␤-galactosidase expression after low multiplicity infection, however, high multiplicity infection led to effective transduction without enhancer stimulation. This raised the hypothesis that high multiplicity infection itself was able to modify the transcriptional environment to augment expression from the CMV-IEP.
In this study we have investigated whether high multiplicity infection with a replication-deficient adenoviral vector expressing no transgene (AdBgl11) could activate NFB in human VSMCs. Activation of NFB by this mechanism would be expected to augment expression from the CMV-IEP and induce expression of cellular genes with NFB response elements such as the adhesion molecule ICAM-1. Demonstration of the ability of high adenoviral loads to stimulate NFB-dependent gene expression may explain the link between the high adenoviral loads needed to achieve efficient transduction using adenoviruses driven by the CMV-IEP and the inflammatory responses which accompany them. 
Results

Activation of NFB by AdBgl11
Activation of NFB was assessed by immunofluorescence using an antibody to the nuclear localisation signal of the p65 subunit (Figure 2) . A faint nuclear signal was observed in unstimulated human VSMCs, although a strong nuclear signal was seen after stimulation with 50 ng/ml PMA. Infection of VSMCs with AdBgl11 at 1000 p.f.u. per cell also led to a marked increase in nuclear staining, however, the intensity of this staining was not as great as that seen with PMA. An increase in nuclear staining was not observed after infection with AdBgl11 at 10 p.f.u. per cell (data not shown).
Infection with AdBgl11 augments expression from the CMV-IEP The following strategies were used to stimulate ␤-galactosidase expression 24 h after infection with RAd35␤Gal. Initial experiments were performed by stimulation of cells with 50 ng/ml PMA and a 7.4-fold augmentation of ␤-galactosidase expression in cell extracts was observed. The NFB inhibitor TLCK given at 100 m was able to inhibit this PMA response if given before the PMA (84% attenuation) but had no inhibitory action if given after PMA stimulation (3% attenuation) (Figure 3a) . This is consistent with inhibition of the proteolytic breakdown of I-B which is able to reform the inactive complex with p65/p50 but which is unable to inhibit active NFB after it has reached the nucleus. When human VSMCs were stimulated with AdBgl11 at 1000 p.f.u. per cell a 3.8-fold augmentation of ␤-galactosidase expression was seen and this response was 99% attenuated by pretreatment of the cells with 100 m TLCK ( Figure 3b ). Infection with AdBgl11 alone did not result in detectable ␤-galactosidase activity in VSMC extracts. Thus, a second adenovirus expressing no transgene was able to augment expression from an adenoviral vector driven by the CMV-IEP and inhibition of NFB activation using TLCK was able to attenuate this effect.
Effect of UV irradiation of the white adenovirus UV irradiation was used to investigate whether gene expression from AdBgl11 was required to augment expression from the CMV-IEP. Initial experiments were performed to determine the duration of UV exposure needed to inhibit ␤-galactosidase expression from RAd35␤Gal when subsequently used to infect human VSMCs at 1000 p.f.u. per cell. UV irradiation of 1 ml of 2 × 10 8 p.f.u./ml RAd35␤Gal for 10 min and subsequent infection of 2 × 10 5 human VSMCs reduced the proportion of transduced VSMCs from 100% to 0% (data not shown). Thus, 10 min irradiation led to at least a 1000-fold decrease in the level of gene expression from RAd35␤Gal and this duration of irradiation was used for subsequent experiments with the 'white' adenovirus AdBgl11.
Human VSMCs were infected with RAd35␤Gal at 100 p.f.u. per cell and stimulated with AdBgl11 at 1000 p.f.u. per cell 24 h later. Stimulation with AdBgl11 at 1000 p.f.u. per cell resulted in a 3.7-fold augmentation of ␤-galactosidase expression in VSMC extracts although a 2.9-fold increase was observed when cells were stimulated with UV-irradiated AdBgl11 (Figure 4) . Thus, UV irradiation did not substantially reduce the ability of AdBgl11 to augment gene expression from the CMV-IEP. 
Infection with AdBgl11 augments ICAM-1 expression
To determine the effects of PMA, TNF␣ and AdBgl11 suspensions on ICAM-1 expression, human VSMCs were evaluated by flow cytometric analysis 24 h after a 2-h period of stimulation. Incubation of human VSMCs with 50 ng/ml PMA and 10 ng/ml TNF␣ led to a 3.5-fold and 4.8-fold increase, respectively, in the mean fluorescence when stained with an antibody to human ICAM-1. A 1.9-fold augmentation of ICAM-1 was observed when human VSMCs were incubated with AdBgl11 at 1000 p.f.u. per cell but no up-regulation was observed after infection at 10 p.f.u. per cell. In addition, pretreatment of human VSMCs with 100 m TLCK resulted in a 68% attenuation of the increase in ICAM-1 fluorescence induced by AdBgl11 at 1000 p.f.u. per cell. This effect of pretreatment with TLCK is consistent with the hypothesis that the AdBgl11 induced up-regulation of ICAM-1 was mediated by NFB. These data are illustrated in Figure 5 .
Discussion
We have demonstrated that infection of human VSMCs with a replication-deficient adenoviral vector expressing no transgene at 1000 p.f.u. per cell resulted in the activation of NFB. This activation was able to augment gene expression from the CMV-IEP and induced expression of the adhesion molecule ICAM-1. Both of these effects were attenuated when the cells were pretreated with TLCK, a protease inhibitor known to inhibit the activation of NFB. 8 This response is important since high adenoviral loads are often required to achieve effective gene transfer; as we have previously shown that infection at 1000 p.f.u. per cell with RAd35␤Gal was required to transduce 100% of human VSMCs in culture. 9 This ability to activate NFkB may have important implications when replication-deficient adenoviral vectors are used at a high multiplicity of infection.
Viral infection usually initiates a regulated cascade of gene expression and many viruses make use of cellular transcription factors. Immediate-early gene expression is required to initiate cytomegalovirus gene expression and this is, in part, facilitated by the activation of NFB in permissive cells. 10 The activation of NFB following cytomegalovirus infection of human VSMCs has recently been demonstrated and appears to involve the generation of reactive oxygen intermediates. 11 Our data demonstrate that replication-deficient adenoviral vectors activate NFB in human VSMCs following infection at a high multiplicity of infection. Moreover, this effect does not appear to be dependent on gene expression from the adenoviral vector, since augmentation of expression from the CMV-IEP can be observed when VSMCs are stimulated with a UV inactivated virus.
The processes by which high adenoviral loads result in the activation of NFB in human VSMCs are unclear. However, our UV inactivation data which suggest that this is not dependent on gene expression from the vector are supported by the work of McCoy et al 12 who demonstrated the ability of incomplete or inactivated adenoviral particles to induce pulmonary inflammation in mice. A number of potential aspects of adenoviral vector processing by VSMCs may be important in this response. First, the binding of viral particles to cell surface receptors may activate signal transduction pathways; this may involve cell surface integrins known to be involved in adenoviral internalisation 13 or the recently cloned receptor for fiber.
14 Second, the ability of adenoviral particles to disrupt endosomes after internalisation may lead to the intracytoplasmic release of proteolytic enzymes as well as viral DNA, and the activation of NFB may represent the host cell response to this intracellular event. Third, the recognition of unmethylated bacterial CpG sequences has been shown to activate a signalling cascade with activation of NFB and inflammatory gene expression in human macrophages. 15 Thus, this ability of eukaryotic cells to recognise 'foreign' DNA may represent part of the host response to infection.
It is generally recognised that improvements to the current strategies for gene transfer are required if gene therapy is to become a clinical reality. Recent experimental work has highlighted two other important aspects of adenoviral vector biology with the aim of improving the effectiveness of experimental gene transfer. First, breakthrough expression of native adenoviral genes in E1-deleted vectors has been implicated in the unwanted immune response following gene delivery. 16 The initial promise that 'second generation' vectors (E2a deleted) may improve the prospects for adenovirus-mediated gene transfer has not materialised, however, adenoviral vectors with more extensive deletions are currently under evaluation. 17 Second, the expression of non-autologous transgenes has been reported to be responsible for important immune responses which may limit the duration of transgene expression. 18 This hypothesis does not explain the inflammatory response and disappointing duration of transgene expression documented in clinical trials when human sequences were incorporated into adenoviral vectors. We believe our data demonstrating the ability of the vector alone to stimulate NFB-dependent gene expression highlights a fundamental limitation when replication-deficient adenoviruses are used at a high multiplicity of infection. However, these findings coupled with our previous data 9 demonstrating undetectable gene expression from the CMV-IEP after successful adenovirus-mediated gene delivery highlights the concept that more potent promoters may allow effective transduction using substantially lower viral loads. Thus, strategies aimed at reducing the 'virion burden' on host cells, possibly with the use of more effective promoters which are not critically dependent on NFB, represent another approach to the refinement of adenoviral vectors in experimental gene transfer.
Materials and methods
Cell culture
Human vascular smooth muscle cells (VSMCs) were grown from sections of aorta discarded at transplantation using an explant method. 9 VSMCs were grown in medium M199 with 20% fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin B (Sigma, Poole, UK). Subcultured cells were split 1:2 using trypsin/EDTA and those between passages 5 and 12 were used in these studies. Positive staining with an antibody to anti-␣ smooth muscle actin (Sigma) was used to confirm that the cells were VSMCs.
Replication-deficient adenoviral vectors
A replication-deficient adenoviral vector expressing no transgene (AdBgl11) was kindly provided by Dr JM Wilson. 19 The replication-deficient adenoviral vector RAd35␤gal, expressing ␤-galactosidase under the control of the human cytomegalovirus major immediate-early promoter (−299 to +65) has been previously described. 20 The viruses were grown on 293 cells, purified by caesium density gradient centrifugation and dialysed, before storage at −70°C. Plaque assay on 293 cells was used to quantify the viral stocks.
Immunofluorescence Human VSMCs in culture were plated on to cover slips and maintained in 0.5% serum for 48 h to induce quiescence. The cells were stimulated with phorbol-12-myristate-13-acetate (PMA) (Sigma) or adenoviral suspensions for 2 h and then washed with ice-cold PBS before being fixed with 3% paraformaldehyde in PBS at 4°C for 45 min. The cells were washed twice with PBS and permeabilised with 0.5% NP40 in PBS for 3.5 min at room temperature. After being washed three times with PBS the cells were incubated overnight with a blocking solution of 3% BSA in PBS at 4°C. The following day the cells were incubated with an antibody to the p65 subunit of active NFB (Boehringer Mannheim, Lewes, UK) at 5 mg/ml for 1 h at room temperature. After removal of this primary antibody, cells were incubated with a secondary antibody mouse FITC conjugate for 30 min at room temperature, then washed three times in PBS. The cells were rinsed with bisbenzimide (1.25 mg/ml) (Sigma), washed with PBS, mounted on to the cover slips and examined using a Zeiss Axioskop fluorescence microscope (Zeiss, Oberkochen, Germany). Control experiments were performed with a mouse IgG antibody to detect any background staining.
␤-Galactosidase expression from RAd35␤Gal
The aim of these experiments was to evaluate the effect of an adenoviral vector expressing no transgene (AdBgl11) on ␤-galactosidase expression from an adenoviral vector driven by a promoter with NFB response elements (RAd35␤Gal).
Human VSMCs were maintained in M199 containing 0.5% FCS for 48 h to induce quiescence, then washed with Earl's balanced salt solution (EBSS) (Gibco, Paisley, UK) before being infected with 1 ml of RAd35␤Gal at 100 p.f.u. per cell in Optimem (Gibco) for 90 min at 37°C. After removal of the RAd35␤Gal, the cells were washed three times with EBSS then maintained in M199 with 0.5% FCS. After 24 h the medium was removed and the cells were stimulated with either the 'white' adenovirus AdBgl11 or 50 ng/ml PMA for 90 min at 37°C. The cells were washed in the same way and maintained in M199 with 0.5% FCS for a further 48 h. Cell extracts were prepared and ␤-galactosidase activity evaluated using an ONPG assay. 9 In addition, the effect of NFB inhibition was investigated by incubation with 100 m TLCK (Sigma) for 30 min before stimulation with PMA or AdBgl11.
Adenoviral UV irradiation was performed by exposing viral suspensions in 1 ml of medium exactly 10 cm from an inverted UV transilluminator (Chromato-Vue, UVP, London, UK) in a tissue culture hood for variable periods of time. These irradiated viral samples were then used to infect human VSMCs.
Flow cytometric evaluation of ICAM-1 expression Human VSMCs were maintained in M199 with 0.5% FCS for 48 h to induce quiescence and used at 50% confluence. Flow cytometric analysis of ICAM-1 expression was performed 24 h after stimulation with 10 ng/ml TNF␣ (Promega, Southampton, UK), 50 ng/ml PMA or suspensions of AdBgl11 for 2 h. The cells were harvested by trypsinisation and washed twice in PBS with 1% BSA at 4°C. After centrifugation, the cell pellet was resuspended in 100 l of a FITC-conjugated monoclonal antibody to human ICAM-1 (R&D Systems, Abingdon, UK) at a concentration of 10 g/ml for 30 min at room temperature. The cells were then washed three times in PBS with 1% BSA at 4°C and finally resuspended in 500 l PBS, before being analysed promptly by flow cytometry (Becton Dickenson FACSort, Oxford, UK).
